HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Henkel

This article was originally published in The Rose Sheet

Executive Summary

In preliminary first quarter results, Dusseldorf, Germany company announces that the cosmetics and toiletries business achieved organic sales growth of 3 percent to about $939 million, and operating profit advanced 3.4 percent to $117.4 million. A 19 percent decrease in organic sales of the adhesives technology business dragged total organic sales down 7 percent to $4.24 billion, though net sales increased 3 percent. Operating profit declined 32.8 percent to $280.4 million. Though the firm says it is dissatisfied with its results, it has the strength to emerge from the difficult economic environment and believes 2009 will be a "major step towards achieving our long-term targets.

You may also be interested in...



Roche's Tecentriq Disappoints In Ovarian Cancer Study

PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.

Greater Uptake Must Become Belgium’s ‘New Normal’

Increased uptake for generics and biosimilars must become Belgium’s “new normal” in the wake of the coronavirus crisis, local off-patent industry association Medaxes has argued.

Biologicals Join List Of EU Medicines Requiring Nitrosamine Evaluation

Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.

UsernamePublicRestriction

Register

ID1131499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel